KEYMED BIOSCIENCES -0001 Net Asset Quality Index
KEYMED BIOSCIENCES -0001 net asset quality index. KEYMED BIOSCIENCES -0001 (64Z) has a Net Asset Quality Index of 65.8% as of December 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of €4.22 Billion minus total liabilities of €1.44 Billion yields net assets of €2.77 Billion. A higher index indicates a stronger, lower-leverage balance sheet. See 64Z net assets for net asset value and shareholders' equity analysis.
Quality Index
Net Assets
Total Assets
Total Liabilities
Net Asset Quality Index of KEYMED BIOSCIENCES -0001 (2021–2025)
Net asset quality index of KEYMED BIOSCIENCES -0001 from 2021 to 2025. This chart shows how KEYMED BIOSCIENCES -0001's Net Asset Quality Index has evolved across 5 annual periods from 2021 to 2025. As of December 2025, the index stands at 65.8%, representing net assets of €2.77 Billion against total assets of €4.22 Billion EUR. Check 64Z intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
KEYMED BIOSCIENCES -0001 Net Asset Quality Index by Year (2021–2025)
KEYMED BIOSCIENCES -0001 net asset quality index by year from 2021 to 2025. The table below presents the year-by-year Net Asset Quality Index for KEYMED BIOSCIENCES -0001 from 2021 to 2025, covering 5 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see market value of KEYMED BIOSCIENCES -0001.
| Year | Quality Index | Net Assets (EUR) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 65.8% | €2.77 Billion | €4.22 Billion | €1.44 Billion | ▲ +0.1 pp |
| 2024 | 65.7% | €2.48 Billion | €3.77 Billion | €1.29 Billion | ▼ -11.2 pp |
| 2023 | 76.9% | €2.99 Billion | €3.88 Billion | €896.11 Million | ▼ -8.0 pp |
| 2022 | 84.9% | €3.34 Billion | €3.93 Billion | €593.10 Million | ▼ -7.7 pp |
| 2021 | 92.7% | €3.65 Billion | €3.93 Billion | €289.07 Million | — |